Considerations for Biopharma Under a First-Inventor-to-File Regime

The America Invents Act brings many significant changes to US patent law, the most fundamental of which is the shift from a first-to-invent system to a first-inventor-to-file system. Kenley K. Hoover, Ph.D., a director at the intellectual property law firm Sterne, Kessler, Goldstein & Fox P.L.L.C., discusses issues and challenges the First-Inventor-to-File regime has brought to the biotechnology industry, as well as the strategies that members of the biotechnology sector have adopted in response to these challenges.

Embed Video

Copy